Disease Landscape and Forecast Insights

Abstract Introduction: With a growing number of biosimilars in development and the launch of the first FDA-approved products in 2015, biosimilars are set to gain an increasing share of the…

Inflectra/Remsima (Germany) Wave 3 is the third in a series of syndicated reports designed to track physician perception and uptake of Hospira’s Inflectra and Mundipharma’s Remsima, two…

The regulatory and market access environment for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, staying ahead of the similarities and…

LaunchTrends: Zarxio (Wave 2) is the second in a series of syndicated reports designed to track physician perception and uptake of Sandoz’s Zarxio (filgrastim-sndz), a biosimilar of Amgen’s…

The biosimilars space is expected to become increasingly competitive as reference brand companies try to retain market share in the face of their product’s dwindling patent life and biosimilar…

“LaunchTrends®: Inflectra/Remsima (Wave 2) is the second in a series of syndicated reports designed to track physician perception and uptake of Hospira’s Inflectra and Mundipharma’s Remsima,…

Abstract

In recent years, biosimilars of epoetin alfa and filgrastim have been approved and launched in major markets. Uptake of these products among oncologists is increasing, driven by payers and…

Nephrologists and endocrinologists in Europe have had the opportunity to use biosimilar erythropoiesis-stimulating agents (ESAs) and human growth hormone (hGH), respectively, for several years, but…

Biologics prescribed by rheumatologists and gastroenterologists are among the most commercially successful biopharmaceutical products in the world. These biologics are a prime target for biosimilar…

LaunchTrends®: Inflectra/Remsima (Wave 1) is the first in a series of syndicated reports designed to track physician perception and uptake of Hospira’s Inflectra and Mundipharma’s Remsima, two…

Gaining physician confidence is critical to securing a meaningful position in developed markets; therefore, understanding their concerns about biosimilar products should be an important part of…